JAMA Network
About The Study: The findings of this randomized clinical trial including 2,200 adolescents indicate that the NVX-CoV2373 (Novavax, Inc.) COVID-19 vaccine is safe, immunogenic, and efficacious in preventing COVID-19, including the predominant Delta variant, in adolescents.
Authors: German Anez, M.D., of Novavax, Inc., in Gaithersburg, Maryland, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.9135)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
